The rat acute-phase protein α2-macroglobulin plays a central role in amifostine-mediated radioprotection.
Previously we reported that elevated circulating concentrations of the acute-phase (AP) protein α(2)-macroglobulin (α(2)M), either as typically occurring in pregnant female rats or after administration to male rats, provides radioprotection, displayed as 100% survival of experimental animals exposed to total-body irradiation with 6.7 Gy (LD(50/30)) x-rays, that is as effective as that afforded by the synthetic radioprotector amifostine. The finding that amifostine administration induces a 45-fold increase in α(2)M in the circulation led us to hypothesise that α(2)M assumes an essential role in both natural and amifostine-mediated radioprotection in the rat. In the present work we examined the activation of cytoprotective mechanisms in rat hepatocytes after the exogenous administration of α(2)M and amifostine. Our results showed that the IL6/JAK/STAT3 hepatoprotective signal pathway, described in a variety of liver-injury models, upregulated the α(2)M gene in amifostine-pretreated animals. In both α(2)M- and amifostine-pretreated rats we observed the activation of the Akt signalling pathways that mediate cellular survival. At the cellular level this was reflected as a significant reduction of irradiation-induced DNA damage that allowed for the rapid and complete restoration of liver mass and ultimately at the level of the whole organism the complete restoration of body weight. We conclude that the selective upregulation of α(2)M plays a central role in amifostine-provided radioprotection.
Mirjana
Mihailović
M
Department of Molecular Biology, University of Belgrade, Belgrade, Serbia. mista@ibiss.bg.ac.rs
Goran
Poznanović
P
Nevena
Grdović
G
Melita
Vidaković
V
Svetlana
Dinić
D
Ilijana
Grigorov
G
Desanka
Bogojević
B
D000209:Acute-Phase Proteins; D004999:Amifostine / Q000008:administration & dosage*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D002478:Cells, Cultured; D005260:Female; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects*; D008297:Male; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D014916:Whole-Body Irradiation; D000511:alpha-Macroglobulins / Q000008:administration & dosage*
D000209:Acute-Phase Proteins; D011837:Radiation-Protective Agents; D000511:alpha-Macroglobulins; D051057:Proto-Oncogene Proteins c-akt; D004999:Amifostine